The Hatch-Waxman Act, also known as the Drug Price Competition and Patent Term Restoration Act of 1984, was enacted to promote the production of generic drugs and safeguard the rights of pharmaceutical companies that develop new medications. Under this law, generic drug manufacturers are permitted to utilise the same active ingredients as brand-name drugs, but they must demonstrate that their product is equivalent to the original drug. Additionally, the law grants patent extensions to brand-name drugs to compensate for the time required to obtain FDA approval, and it allows generic drug manufacturers to challenge the validity of these patents. This legislation has contributed to the affordability of prescription drugs for consumers and has fostered competition within the pharmaceutical industry.
The Hatch-Waxman Act, also known as the Drug Price Competition and Patent Term Restoration Act of 1984, was enacted by the United States Congress to promote the development of generic drugs and safeguard the interests of pharmaceutical companies. This legislation enables generic drug manufacturers to seek approval for their products by demonstrating equivalence to an existing brand-name drug. This streamlined process, known as the Abbreviated New Drug Application (ANDA) process, facilitates the entry of generic drugs into the market. Additionally, the Hatch-Waxman Act allows pharmaceutical companies to extend the patent life of their drugs by applying for a patent term extension, which can prolong exclusivity for up to five years. For instance, if a pharmaceutical company’s patent for a drug is due to expire in three years, they can request a two-year extension, resulting in a total of five years of exclusive rights to sell the drug. This legislation has been instrumental in fostering competition within the pharmaceutical industry and enhancing affordability for consumers. By facilitating the entry of generic drugs, the Hatch-Waxman Act has contributed to reducing the cost of prescription medications.
The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, is a United States federal law that encourages the development of generic drugs while also protecting the interests of pharmaceutical patent holders.
The Act allows generic drug manufacturers to file an Abbreviated New Drug Application (ANDA) to demonstrate that their product is bioequivalent to a brand-name drug that is already on the market. This allows for a faster and less expensive approval process for generic drugs.
Patent term restoration allows for the extension of a patent’s term to compensate for the time lost during the regulatory approval process for a new drug.
The Act provides for a period of market exclusivity for brand-name drugs, during which generic competitors are prohibited from entering the market.
The Act includes provisions for resolving patent disputes between brand-name and generic drug manufacturers, including the use of the “paragraph IV certification” process.
The Act’s provisions for generic drug approval and market entry can lead to lower drug prices by increasing competition in the pharmaceutical market.
To obtain patent term restoration, a pharmaceutical patent holder must demonstrate that the regulatory approval process for their new drug caused a delay in the effective term of their patent.
The Act’s provisions for expedited approval of generic drugs can lead to increased availability of lower-cost alternatives to brand-name drugs.
The Act places limits on the total extension of a patent’s term, as well as the timing of the application for patent term restoration.
The Act seeks to strike a balance between promoting innovation and competition in the pharmaceutical industry, ultimately benefiting consumers by increasing access to affordable medications.
This site contains general legal information but does not constitute professional legal advice for your particular situation. Persuing this glossary does not create an attorney-client or legal adviser relationship. If you have specific questions, please consult a qualified attorney licensed in your jurisdiction.
This glossary post was last updated: 17th April 2024.
To help you cite our definitions in your bibliography, here is the proper citation layout for the three major formatting styles, with all of the relevant information filled in.
- Page URL:https://dlssolicitors.com/define/drug-price-competition-and-patent-term-restoration-act-of-1984/
- Modern Language Association (MLA):Drug Price Competition And Patent Term Restoration Act Of 1984. dlssolicitors.com. DLS Solicitors. May 09 2024 https://dlssolicitors.com/define/drug-price-competition-and-patent-term-restoration-act-of-1984/.
- Chicago Manual of Style (CMS):Drug Price Competition And Patent Term Restoration Act Of 1984. dlssolicitors.com. DLS Solicitors. https://dlssolicitors.com/define/drug-price-competition-and-patent-term-restoration-act-of-1984/ (accessed: May 09 2024).
- American Psychological Association (APA):Drug Price Competition And Patent Term Restoration Act Of 1984. dlssolicitors.com. Retrieved May 09 2024, from dlssolicitors.com website: https://dlssolicitors.com/define/drug-price-competition-and-patent-term-restoration-act-of-1984/
Our team of professionals are based in Alderley Edge, Cheshire. We offer clear, specialist legal advice in all matters relating to Family Law, Wills, Trusts, Probate, Lasting Power of Attorney and Court of Protection.
All author posts